Evaluating CALR Allele Burden in Myeloproliferative Neoplasms

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the significance of monitoring CALR allele burden as a molecular marker for disease progression in patients with CALR-mutated myeloproliferative neoplasms (MPNs). It aims to analyze a multicenter cohort of 260 patients, collecting blood samples at diagnosis and annually for three years to quantify CALR allele burden. The study will also assess a clinicobiological score to determine disease progression in patients with Essential Thrombocythemia and Myelofibrosis, building on previous findings from a local study that highlighted the prognostic value of CALR mutation quantification.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* adults (age ≥18 years),
* affiliated to the national social security system,
* with CALR mutated myeloproliferative neoplasm diagnosed between 2006 - 2020,
* for which at least one sample is available at the time of diagnosis or before cytoreductive treatment,
* who signed the consent to participate in the study,
* included, or consenting to be included, in the national clinical-biological database of France Intergroupe Syndrome Myéloprolifératifs (FIM).

Exclusion Criteria:

* patient with another active hematological disease or cancer at the time of diagnosis,
* person subject to legal protection scheme or incapable of giving consent.

Where it's running

• CHU Angers
  Angers, France Recruiting
• Chu Bordeaux
  Bordeaux, France Recruiting
• Chu Brest
  Brest, France Recruiting
• Ch Cholet
  Cholet, France Recruiting
• Ch Le Mans
  Le Mans, France Recruiting
• Ch Morlaix
  Morlaix, France Recruiting

Study contacts

• Study coordinator: Laurane COTTIN, Doctor
• Email: Laurane.Cottin@chu-angers.fr
• Phone: +33 2 41 35 53 53

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Registry of Asian patients with myeloproliferative neoplasms

  This study is collecting information from Asian patients with myeloproliferative neoplasms to learn more about their condition and how different treatments work for them.

  Recruiting The University of Hong Kong · Hong Kong · NCT05882773

• Characterizing Monocytes in Blood Disorders

  This study is trying to learn more about the role of certain blood cells called monocytes in patients with specific blood disorders to see how they might affect the disease and treatment options.

  Recruiting University Hospital, Angers · Angers, Maine et Loire and 2 other locations · NCT06361641

• Finding the best dose of N-Acetylcysteine for patients with blood disorders

  This study is testing the best dose of N-Acetylcysteine to see if it can help people with certain blood disorders feel better while they continue their usual treatments.

  Recruiting Phase 1/2 University of California, Irvine · Irvine, California and 1 other locations · NCT05123365

• Combining decitabine with ruxolitinib, fedratinib, or pacritinib for treating advanced myeloproliferative neoplasms

  This study is testing if combining decitabine with other medications can help patients with advanced blood cancers get ready for a stem cell transplant.

  Recruiting Phase 2 University of Washington · Seattle, Washington · NCT04282187

• Caris Chromoseq data collection for AML, MDS, and MPN

  This study tests how well the Caris Chromoseq assay helps categorize risk in patients with AML, MDS, or MPN compared with standard tests.

  Recruiting Caris Science, Inc. · Phoenix, Arizona · NCT07680868

• A Phase 3 Test of INCA033989 vs Best Available Therapy for Essential Thrombocythemia with CALR Mutation

  This phase 3 study tests whether INCA033989 can help people with essential thrombocythemia who have a CALR mutation and have already had cytoreductive therapy, compared to the best available treatment.

  Recruiting at 5 sites Phase 3 Incyte Corporation · Birmingham, Alabama and 191 other locations · NCT07623200

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.